KR101468658B1 - Compositions for the prevention and treatment of obesity comprising extracts of Gambigyeongsinhwan (1) as an active ingredient - Google Patents

Abstract

The present invention relates to a pharmaceutical composition for prevention and treatment of obesity, which contains an extract of corn, wilt and cormus as an active ingredient, and a health functional food for prevention and improvement of obesity.
The extracts of Ulgum, Kwangpo and cormus of the present invention are effective in reducing weight loss, lowering dietary efficiency, decreasing fat weight, decreasing serum ALT, HDL-cholesterol, LDL-cholesterol and triglyceride glucose, decreasing the number and size of fat cells, , A drug for preventing and treating obesity, a functional food, and the like.

Description

[0001] The present invention relates to a composition for prevention and treatment of obesity,

The present invention relates to a composition for preventing and treating obesity. More specifically, the present invention relates to a pharmaceutical composition for prevention and treatment of obesity, which comprises an extract of Ulgum, bagasse and cormorant as an active ingredient, and a health functional food for obesity prevention and improvement based on the fact that the extract of Ulgum, .

Obesity can be defined as a kind of disease that pose health risks due to excessive body fat accumulation. According to the International Obesity Task Force (IOTF), about 1.7 billion people, or one-fourth of the world's population, need to lose weight and become serious social problems for both developed and developing countries (Hue et al, 1990; James et al, 2001; Mokdad et al, 2003). According to US statistics, two-thirds of the US population is overweight or obese. In Korea, the obesity population is increasing, and the Korean Society of Obesity (KSSO) has one-third of the total population in Korea. The Framingham Heart Study reported that the mortality rate increased by 1% with an increase of 1 pound (0.45 kg) in adults aged 30 to 42 and increased by 2% at 50 and 62 years (Hubert et al. al., 1986). Until now, various animal models have been developed and used in the researches related to the mechanism of illnesses such as obesity and diabetes, prevention, and treatment, mainly from the Middle Eastern water such as pigs, sheep and dogs to small animals including rodents and rodents (Bain et al., 2004). In addition, there is a growing interest in this research (Spiegelaman et al., 1996; Chua et al., 1997; Carey et al.

Ob / ob, yellow, and NZO mice are characterized by hyperglycemia accompanied by obesity, ketoacidosis and hyperinsulinemia, while db / db and spiny mice are characterized by hyperglycemia Bull et al., 1977; Shimabukuro et al., 1998; Smith et al., 2000). However, the incidence of hyperglycemia is low.

According to the statistics of Japan, 30 ~ 60% of lifestyle-related diseases (adult diseases) are caused by obesity and the medical expenses are 2 trillion yen (KRW 25 trillion) to reduce 5 kg weight. Is one in four to five people, and is expected to continue to increase in the future. This tendency is a more serious national problem in the United States and Europe. In Korea, eating habits have been widespread and the incidence of childhood infants has increased rapidly. There have been more opportunities to eat high-fat, high-calorie foods with a good life, Because the energy is so small, obesity is increasing rapidly. In addition, for the beauty effect of young women, after marriage, women are also overweight or obese, so they are working hard to maintain their shape as they were when they were young.

In recent years, obesity in Korea has increased about 1.6 times over the past 10 years. According to the experience of advanced countries, the obesity population will increase more rapidly in the future (2006 Ministry of Health and Welfare). BMI (kg / m2) <18.5, normal: 18.5 ≤ BMI (kg / m2) <25, Obesity: The prevalence of obesity in Korea was over 30 years old (31.8% The prevalence of obesity was 26.3% in 1998, 29.6% in 2001, and 31.7% in 2005. The prevalence of obesity in Korea was higher in the 40s and 50s than in the 50s and 60s, In the case of women, the change from 27% in 1998 to 28% in 2005 was insignificant, but in men, it increased from 25% in 1998 to 32.3% in 2001 and 35.1% in 2005 appear.

In addition, the obesity rate of children and adolescents in 2005 (obesity index: obesity index ≥ 20, obesity index = (actual weight - 50th percentile weight by height) / 50th percentile weight by height * 100 50th percentile weight by height " (10.2%), males (11.7%) and females (8.4%), and the percentages of males (0 ~ 6 years old) before admission by age were higher than males The obesity rate increased from 22% to 24% in boys and 13% to 14% in girls. The proportion of obesity increased in all age groups compared with 1998, and in middle school students and high school students Obesity rates were 1.9 times and 2.3 times higher, respectively.

The fact that obesity and overweight are the biggest factors of medical and economic burden has also been demonstrated, and it has come to the point when the public and administrative institutions are also aware of it. Although there is a lot of information development due to the development of medical technology, it is a problem that can not be solved in the existing medical field of narrow meaning, and it is recognized that prevention is urgently needed by improvement of eating habits and improvement of lifestyle such as exercise. Even in the standard weight range, there is a shocking report that the ratio of diabetes, gout, and liver disease is about 40% when the weight increases dramatically during the age of 18 to 20 years. In advanced countries living in the era of predation, without the clear nutritional control, the US government and the Japanese government have prepared nutritional measures and nutrition policies for obesity countermeasures.

Obesity is associated with a higher proportion of obesity-related medical expenses among the total medical expenses due to increased incidence of adult diseases and chronic degenerative diseases. In developed countries, 2 to 7% of the total medical expenses are caused by overweight and obesity, Including intangible factors such as unofficial medical and diet foods, exercise, indirect costs such as impaired productivity due to obesity, poor quality of life due to obesity, and suffering from disease, the socio-economic costs of obesity are higher .

In addition, regarding the energy-related lipid intake, people who have high cholesterol in obesity energy ratio inhibit cholesterol intake to 300 mg / day, and fat peroxide is the first cause of lifestyle-related diseases, so vitamin E, C and carotenoids There is a guideline that it is very important to consume antioxidants starting with antioxidant vitamins. Therefore, the food industry and the pharmaceutical industry are urgently required to develop foods and medicines in the 21st century for obesity measures.

Most obesity is a simple obesity, which is the main cause of overeating and lack of exercise, and the other is distinguished only by the symptom ratio, which is the cause of endocrine diseases. Simplicity The cause of obesity is obviously difficult to say in a word, but it is the wrong diet such as overeating, binge eating, snacking, midnight snack, irregular meal, and side effects of lack of exercise. Obesity is a cause of various diseases by accumulating large amounts of body fat, moisture, and wastes in the body because it is not used or excreted in the body. The principles of the diet method developed in the past include simple identification or fasting, limiting the absorption of fat, inhibiting the synthesis of fat and reducing excess appetite, facilitating bowel movements, and providing a feeling of satiety.

Studies on obesity have been published (Bhabani et al, 2002), and in the United States in 2005, MCH-R1 (Melanin Concentrating Hormone Receptor1) was included in studies on the isolation and purification of HCA from Garcinia cambogia in India in 2002 (Palani et al., 2005), a biweekly study of biaryl ureas (Biaryl Ureas) for the treatment of obesity. In 2005, Japan announced the results of research on reduction of weight gain in rats due to consumption of soy protein and reduction of intake of triglycerides and reduction of cholesterol (Tachibana et al, 2005). Studies are underway.

Anti-obesity materials include appetite suppressants such as Dexflenfluramine, Phenylalanine, Tyrosine and Methionine, Fatty binder (Orlistat), Chitosan, Fat burning Zero Silbutramine, Ephedrine, Caffeine and Zilchin, Garcinia Cambogia Fruit, L-Carnitine, Dietary Fiber to Control Gut Function: Chanopodium, Glucomannan Each Lactomanan, And Chromiumpicolinate. However, although these drugs are somewhat recognized for their efficacy (Pittler et al, 2004), there are side effects of temporary weight loss, rapid weight loss, drug-induced heart, blood pressure, and nervous system.

Therefore, there is a need to develop new substances that are safe for the human body, have no side effects, and have an efficacy equal or superior to that of conventional obesity inhibiting substances, using natural products.

The inventors of the present application developed a pharmaceutical composition for prevention and treatment of obesity, which contains an extract of Ulgum, baguette and cormorant as an effective ingredient, in order to safely and adversely affect the human body, The present inventors have completed the present invention by confirming the effect thereof through weight change, dietary efficiency, fat weight, blood biochemical analysis, morphology and histological analysis.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing and treating obesity.

It is also an object of the present invention to provide a health functional food for preventing and improving obesity.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing and treating obesity, which comprises an extract of Ulgum, bagasse and cormorant as an active ingredient.

Preferably said extract is water, C &_lt; RTI ID = 0.0 _&gt; To C ₄ Lower alcohols or mixtures thereof as a solvent, and more preferably ethanol.

The total weight of the herbal composition may be 0.1 to 80 parts by weight, the weight of the packing may be 0.1 to 40 parts by weight, and the whole corm may be 0.1 to 40 parts by weight.

Further, the dose of the composition may be 0.01 to 1000 mg / kg per body weight.

In addition, the present invention provides a health functional food for preventing and improving obesity containing an extract of Ulgum, bagasse and cormorant as an active ingredient.

The extracts of Ulgum, Kwangpo and cormus of the present invention are effective in reducing weight loss, lowering dietary efficiency, decreasing fat weight, decreasing serum ALT, HDL-cholesterol, LDL-cholesterol and triglyceride glucose, decreasing the number and size of fat cells, And may be useful for medicines and functional foods for prevention and treatment of obesity.

FIG. 1 is a graph showing a change in body weight in a high fat diet mouse obesity model. Data were expressed as means ± SD. * P <0.05, ** P <0.01 and *** P <0.001, respectively. GGH (1) means the reduced-amplitude new ring (1).
FIG. 2 is a graph showing the reduction in dietary efficiency in a high fat diet mouse obesity model. Data were expressed as means ± SD. * P <0.05, ** P <0.01 and *** P <0.001, respectively. ### P <0.001 is a significant difference compared to the normal.
3 is a graph showing the fat tissue weight in a high fat diet mouse obesity model. EAT = epididymal adipose tissue; RAT = retroperitoneal adipose tissue (white adipose tissue surrounding the retroperitoneal wall); IAT = inguinal adipose tissue; BAT = brown adipose tissue.
FIG. 4 is a graph showing the AST concentration in fasted state plasma in a high-fat mouse obesity model.
FIG. 5 is a graph showing the concentration of ALT in fasted state plasma in a high-fat mouse obesity model.
FIG. 6 is a graph showing the concentration of HDL-cholesterol in fasted state plasma in a high-fat mouse obesity model.
7 is a graph showing the concentration of LDL-cholesterol in fasted state plasma in a high-fat mouse obesity model.
8 is a graph showing the concentration of total cholesterol in fasted state plasma in a high fat diet mouse obesity model.
FIG. 9 is a graph showing the concentration of triglyceride in fasted state plasma of a high-fat mouse obesity model.
10 is a graph showing the concentration of free fatty acid in fasted state plasma in a high fat diet mouse obesity model.
FIG. 11 is a graph showing the concentration of glucose in fasted state plasma in a high fat diet mouse obesity model. FIG.
FIG. 12 is a graph showing the concentration of insulin in fasted state plasma in a high-fat mouse obesity model.
13 is a graph showing the concentration of leptin in fasted state plasma in a high fat diet mouse obesity model.
14 is a graph showing the concentration of adiponectin in fasted state plasma in a high-fat mouse obesity model.
15 is a diagram showing a morphological analysis of the white adipose tissue around the genitals.
(A) is a photograph of a section of the epididymal adipose tissue around the genitalia stained with hematoxylin (hematoxylin) and eosin (eosin). (Magnification X 100). (B) is a graph showing the number of cells in the adipose tissue around the genitals. (C) is a graph showing the size of the fat cells around the genitalia. The fat cell size in the fixed region (1,000,000 mu m ² ) was measured by an image analysis system. All values were expressed as means ± SD. ** p <0.01, *** p <0.001 indicate significant difference.
16 is a graph and a photograph showing changes in fat accumulation of liver tissue according to GGH (1) in a high fat diet mouse obesity model. This is a photograph of a section of liver tissue stained with hematoxylin (hematoxylin) and eosin (eosin). * p <0.05, ** p <0.01, *** p <0.001.

The present invention provides a pharmaceutical composition for the prevention and treatment of obesity, which comprises an extract of Ulgum, bagasse and cormorant as an active ingredient.

In the present invention, &quot; glutinous &quot; means Curcuma It has had the scientific name of the longa L., a perennial herbaceous plant belonging to the ginger is native to tropical Asia, and distributed in the country, including Japan, India, China and Indonesia.

The term &quot; kelp &quot; in the present invention means Laminaria japonica It has the scientific name of Aresch and refers to the thorns of kelp.

In the present invention, &quot; mahogany &quot; refers to Amorphophallus rivieri Durieu [A. Konjac K. Koch ] and means the Old Testament herb, the konnyaku.

In the present invention, &quot; obesity &quot; means any condition that poses a risk to health due to excessive body fat accumulation.

The term "prophylactic " as used herein refers to any action that inhibits the formation of obesity or delays progression by administration of the composition of the present invention.

As used herein, the term "treatment" refers to any action in which the symptoms of obesity are alleviated or beneficially altered by the administration of the composition of the present invention.

The koji, the wrapping and the corn of the present invention can be extracted by a known solvent extraction method. For example, water, ethanol, alcohol, propanol, isopropanol, alcohol having 1 to 6 carbon atoms such as butanol, acetone, ether, chloroform, ethyl acetate, Or an organic solvent such as methylene chloride, hexane, cyclohexane, petroleum ether, diethyl ether, and benzene, or a mixed solvent thereof. Preferably water, C &_lt; RTI ID = 0.0 _&gt; To C ₄ Lower alcohols or a mixture thereof may be used as a solvent, and most preferably ethanol may be extracted.

In the extract of the present invention, the extract extracted by the solvent extraction method can be used as it is or can be fractionated by a known method to remove impurities and increase the concentration of the active ingredient. The extract may be concentrated under reduced pressure for the efficiency of fractionation. Examples of the solvent for the fraction include alcohols having 1 to 6 carbon atoms such as water, ethanol, ethanol and methanol, ethyl acetate, methylene chloride, dichloromethane, chloroform, n-hexane), diethyl ether, acetone, benzene, or a mixed solvent thereof. Preferably, the solvent is selected from water, n-butanol, ethanol and ethyl acetate, or a mixture thereof It can be fractionated with a solvent. The fraction may be used as it is or may be re-fractionated, and ethyl acetate may be preferably used for the re-fractionation. Particularly, in order to carry out the extraction process more economically, it is preferable to extract once with a single solvent or a mixed solvent, and it is preferable to use an alcohol having a carbon number of 1 to 6 such as water, ethanol, alcohol and methanol, ethyl acetate, methylene chloride, dichloromethane, it is preferable to use any one selected from organic solvents such as n-hexane, diethyl ether, acetone and benzene or a mixed solvent thereof. More preferably, ethanol, alcohol, acetone, ethyl acetate and methylene chloride can be used.

The pharmaceutical compositions according to the present invention may further comprise a pharmaceutically effective amount of corn, wilt and cormorant extracts, or may further comprise one or more pharmaceutically acceptable carriers.

The composition of the present invention can be variously formulated according to the route of administration by a method known in the art together with the pharmaceutically acceptable carrier. Routes of administration include, but are not limited to, oral or parenteral administration. Parenteral routes of administration include, for example, various routes such as transdermal, nasal, peritoneal, muscular, subcutaneous or intravenous.

When the pharmaceutical composition of the present invention is orally administered, the pharmaceutical composition of the present invention may be formulated into a powder, a granule, a tablet, a pill, a sugar, a tablet, a capsule, a liquid, a gel , Syrups, suspensions, wafers, and the like. Examples of suitable carriers include saccharides including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch and potato starch, Cellulose such as methyl cellulose, sodium carboxymethyl cellulose and hydroxypropylmethyl-cellulose, etc., and fillers such as gelatin, polyvinylpyrrolidone and the like. In addition, crosslinked polyvinylpyrrolidone, agar, alginic acid, or sodium alginate may optionally be added as a disintegrant. Further, the pharmaceutical composition may further comprise an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and an antiseptic agent.

In addition, when administered parenterally, the pharmaceutical composition of the present invention can be formulated together with a suitable parenteral carrier according to methods known in the art in the form of injection, transdermal drug delivery, and nasal inhalation. In the case of such injections, they must be sterilized and protected against contamination of microorganisms such as bacteria and fungi. Examples of suitable carriers for injectables include, but are not limited to, solvents or dispersion media containing water, ethanol, polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol, etc.), mixtures thereof and / or vegetable oils . More preferably, suitable carriers include isotonic solutions such as Hanks' solution, Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine, or sterile water for injection, 10% ethanol, 40% propylene glycol and 5% dextrose Etc. may be used. In order to protect the injection from microbial contamination, various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like may be further included. In addition, the injections may in most cases additionally include isotonic agents, such as sugars or sodium chloride. Examples of transdermal dosage forms include ointments, creams, lotions, gels, solutions for external use, pastes, liniments, and air lozenges. By "transdermal administration" as used herein, it is meant that the pharmaceutical composition is locally administered to the skin so that an effective amount of the active ingredient contained in the pharmaceutical composition is delivered into the skin.

These formulations are described in generally known prescription Seo literature ^{(Remington's Pharmaceutical Science, 15 th} Edition, 1975, Mack Publishing Company, Easton, Pennsylvania) in pharmaceutical chemistry.

In the case of inhalation dosage forms, the compounds used according to the present invention may be formulated into a pressurized pack or a pressurized pack using a suitable propellant, for example dichlorofluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gases. It can be conveniently delivered in the form of an aerosol spray from a nebulizer. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve that delivers a metered amount. For example, gelatin capsules and cartridges for use in an inhaler or insufflator may be formulated to contain a compound, and a powder mixture of a suitable powder base such as lactose or starch.

Other pharmaceutically acceptable carriers can be found in Remington's Pharmaceutical Sciences, 19th ed., 1995, Mack Publishing Company, Easton, PA).

Furthermore, the pharmaceutical composition of the present invention can be administered in combination with a known compound having an effect of preventing and treating obesity.

In the present invention, the weight ratio of the koi, the wrap and the cormorant is 0.1 to 80 parts by weight, the total weight of the koi is 0.1 to 40 parts by weight, the cormus is 0.1 to 40 parts by weight, .

The pharmaceutical composition according to the present invention may be administered in a pharmaceutically effective amount. The pharmaceutical compositions according to the present invention may be administered to a patient in a single dose and may be administered by a fractionated treatment protocol in which multiple doses are administered over a prolonged period of time. The term "pharmaceutically effective amount" as used herein refers to an amount that exhibits a higher level of response than a negative control, and preferably refers to an amount sufficient to treat or prevent obesity. The effective amount of the extract according to the present invention may be 0.01 to 1000 mg / kg / day per body weight, but is not limited thereto. However, the pharmaceutically effective amount may be appropriately changed depending on various factors such as the disease and its severity, the patient's age, body weight, health condition, sex, administration route and treatment period.

In addition, the present invention provides a health functional food for preventing and improving obesity containing an extract of Ulgum, bagasse and cormorant as an active ingredient.

According to the present invention, the extract of corn, walnut and cormus may be provided in the form of a food composition for the purpose of improving obesity, obesity complication or metabolic syndrome. The food composition of the present invention includes all forms such as functional food, nutritional supplement, health food and food additives. Food compositions of this type may be prepared in a variety of forms according to conventional methods known in the art.

For example, as a health food, the extract of the present invention itself may be prepared in the form of tea, juice, and drink and then taken for drinking, granulated, encapsulated and powdered. In addition, the extract of the present invention may be mixed with a known substance or active ingredient known to have an effect of improving obesity, obesity complication or metabolic syndrome, and may be prepared in the form of a composition.

 Functional foods also include beverages (including alcoholic beverages), fruits and processed foods (such as canned fruits, bottles, jams, maalmalade, etc.), fish, meat and processed foods such as ham, sausage, ), Breads and noodles (eg udon, buckwheat noodles, ramen noodles, spaghetti, macaroni, etc.), fruit juice, various drinks, cookies, Retort food, frozen food, various kinds of seasoning (for example, soybean paste, soy sauce, sauce, etc.) by adding the extract of the present invention.

In the food composition of the present invention, the preferable content of the above-mentioned corn, walnut and cormorant extracts is not particularly limited, but is preferably 0.01 to 50% by weight in the finally prepared food.

In order to use the extract of the present invention in the form of a food additive, it may be used in the form of a powder or a concentrated liquid.

Hereinafter, the present invention will be described more specifically based on examples. It will be apparent to those skilled in the art that the embodiments are only for describing the present invention in more detail and that the scope of the invention is not limited by these embodiments in accordance with the gist of the present invention.

< Example 1  > Materials and Methods

1-1: Experimental material

(1) Experimental animals

As an animal to be exposed, 35 C57BL / 6N male mice of 8 weeks old supplied from KOATECH (Gyeonggi province, South Korea) were used. Seven rats per group were randomly divided into groups according to their weight ranges and used for the experiments.

The incubation environment was 21 ± 2 ℃ for temperature, 55 ± 5% for humidity, 15 ~ 17 times / hour for ventilation, 150 ~ 300 lux for illumination and 12 hours for light (light: 06:00, light: 18:00) And maintained in a SPF (specific pathogen free) state during the experiment. Solid feed (Harlan, USA) and water were fed free and watered.

(2) Experimental material

The experimental material was a 95% ethanol extract of Sungbyeonggyeonghwan (1). The manufacturing process is as follows (Table 1).

(1) The drug was purchased from Hwangrim Pharmaceutical (Busan, South Korea), and was selected in the School of Oriental Medicine, Dong Eui University.

(2) The pulverized reduced parentheses (1) (1 kg) was ultrasonically extracted with 95% ethanol at 70 ° C for 180 minutes, filtered through a No. 2 filter, and concentrated.

③ Concentration yielded 32.88%.

Chinese medicine name Ingredient % Ugum Curcuma longa  L. 60 Bale (kelp) Laminaria japonica Aresch 20 Mako Amorphophallus rivier  Durieu [A. Konjac  K. Koch ] 20 Total amounts 100

(3) Experimental group  And administration method

Seven male rats were orally administrated with water for obesity control and GGH (1) at 125, 250 and 500 mg / kg for 8 weeks (Table 2).

Group Treatment Number Sex Normal Low fat 7 male High fat + GGH (1) (mg / kg BW) Control water 7 male GGH (1) -1 125 7 male GGH (1) -2 250 7 male GGH (1) -3 500 7 male

1-2: Experimental method

(1) Measurement of weight gain

To determine the changes in weight gain of GGH (1) -1, GGH (1) -2 and GGH (1) -3, the body weight was measured twice weekly for 8 weeks and the weight gain was calculated Respectively.

(2) Dietary efficiency  Measure

To determine whether GGH (1) -1, GGH (1) -2 and GGH (1) -3 were associated with appetite, body weight was measured twice a week, feed intake was measured once a week for 8 weeks, And the dietary efficiency was calculated. Dietary efficiency was calculated by dividing the final weight gain by the total feed intake by substituting into the formula below.

Feed efficiency ratio (FER%) = weight gain (g) / feed intake (g) × 100

As indicated by the formula of diet efficiency, the low body weight gain despite the high intake of diets may be considered to have an obesity modulating effect. Therefore, dietary efficiency can be used as a measure of obesity, and the lower the dietary efficiency, the more effective it is to control obesity.

(3) Blood biochemical analysis

Blood sampling was performed 8 hours after the start of the experiment for 12 hours and then anesthetized with diethyl ether. Then, 1 ml of blood was collected from the abdominal vein and centrifuged at 13,000 rpm for 5 minutes using a high-speed centrifuge (Micro 12, Hanil, Korea) And centrifuged. (AST), alanine aminotransferase (ALT), triglyceride (TG), and total cholesterol (TC) were measured using a biochemical analyzer (Selectra 2, Vitalab, Netherlands) (HDL-cholesterol), low-density lipoprotein cholesterol (LDL-cholesterol), free fatty acid (FFA), glucose, insulin and leptin.

(4) Animal autopsy

After the blood collection, the autopsies were performed to determine the weight of the adipose tissue (the white adipose tissue around the genitalia, the white adipose tissue surrounding the posterior abdominal wall, the subcutaneous adipose tissue around the groin, the brown adipose tissue), liver, pancreas, spleen, heart and kidney, And color were observed.

(5) Morphological analysis of tissue

The tissues isolated from mice were fixed in 10% phosphate-buffered formalin for one day. After washing formalin in water for more than 12 hours, they were incubated for 1 hour in 60% ethanol, 1 hour in 70% ethanol, 1 hour in 80% % ethanol for 1 hour, 95% ethanol for 1 hour, and 100% ethanol for 1 hour. Xylen is applied to the paraffin for 1 hour and then 2 times for 1 hour. After embedding, the tissue was paraffin-sectioned to a thickness of about 3 μm, and the tissue was placed on the slide, followed by hematoxylin-eosin staining. After removing the drainage from the slides and dropping the mounting medium (Sigma, MO, USA), the cover glass was placed on the cover glass with care to prevent air from forming around the tissue and cover glass. Photographs of the tissues and the number and size of adipocytes were analyzed using an image analysis system (Image Pro-Plus, MD, USA).

1-3: Statistical Analysis

All values were expressed as mean ± standard deviation (SD), and statistical significance was verified using the ANOVA one way of OriginLab Version 7.5 (OriginLab Corporation, MA, USA).

< Example 2 > Experimental results

2-1: Weight change

GGH (1) -1, GGH (1) -2, and GGH (1) -1 were significantly lower than those of the control group. -3 (see Fig. 1).

2-2: Dietary efficiency

Compared with the control group, the dietary efficiency of GGH (1) -1 was 13.74%, GGH (1) -2 was 13.06%, and GGH (1) -3 was 17.56%. All of them were statistically significant compared to the control group, and the degree of GGH (1) -3 was higher among the three concentrations (see FIG. 2).

2-3: Fat Weight

GGH (1) -1, GGH (1) -2, and GGH (1) -3 were decreased by 14.80%, 10.28% and 14.88%, respectively, in the peripheral white adipose tissue (EAT) (1) -1, GGH (1) -2, and GGH (1) -3 were 7.86% and 7.86%, respectively, in the case of white adipose tissue surrounding the retroperitoneal wall (RAT) GGH (1) -1 was 8.26%, GGH (1) -2 was 5.48%, and GGH (1) -3 was lower in the groin subcutaneous fat tissue (IAT) than in the control group (1) -1 was 13.26%, GGH (1) -2 was 16.92%, and GGH (1) -1 was significantly decreased in the brown adipose tissue (BAT) compared to the control group ) -3 was 11.90%, indicating that the weight was reduced. (1) -1 and GGH (1) -3 were higher than those of GGH (1) -2. On the other hand, white adipose tissues around the posterior abdominal wall GGH (1) -1 and GGH (1) -3 were higher in GGH (1) -2 than in GGH (1) -1 and GGH (1) -1 and GGH (1) -2, respectively (Fig. 3).

1-4: Blood biochemical analysis

① Serum asparate aminotransferase  ( AST ) Concentration

And there was no statistical significance compared to the control group (Fig. 4).

② Serum field aminotransferase  ( ALT ) Concentration

GGH (1) -3 was statistically significantly lower than that of the control group (FIG. 5).

③ Serum HDL - cholesterol  density

GGH (1) -1 as compared to the control group (FIG. 6).

④ Serum LDL - cholesterol  density

GGH (1) -3 was statistically significantly lower than that of the control group (Fig. 7).

⑤ Serum total cholesterol  density

And there was no statistical significance compared to the control group (Fig. 8).

⑥ Serum triglyceride  density

GGH (1) -1, GGH (1) -2 and GGH (1) -3 were statistically significantly lower than the control group. And it was found to be higher in GGH (1) -3 among the three concentrations (Fig. 9).

⑦ Serum free fatty acid  density

And there was no statistical significance in comparison with the control group (Fig. 10).

⑧ Serum glucose  density

GGH (1) -1, GGH (1) -2 and GGH (1) -3 were statistically significantly lower than the control group. And it was found to be larger in GGH (1) -2 among the three concentrations (Fig. 11).

⑨ Serum insulin  density

And there was no statistical significance compared to the control group (Fig. 12).

⑩ Serum leptin  density

And there was no statistical significance compared to the control group (Fig. 13).

⑪ Serum adiponectin  density

And there was no statistical significance compared to the control group. However, GGH (1) -1 was lower in the GGH (1) -1 than in the control, and GGH (1) -2 and GGH (1) -3 were higher than in the control group (FIG. 14).

2-5: Fat tissue and Liver tissue histology Wow morphology  change

① local organization histology Wow morphology  change

The number and size of adipocytes in GGH (1) -1, GGH (1) -2 and GGH (1) -3 were statistically significant in comparison with the control group. Compared with the control group, the levels of GGH (1) -1 and GGH (1) -3 were higher in proportion to the decrease in body weight and fat weight. GGH (1) -2 and GGH (1) -2 were increased by 23.34%, 15.84% and 25.10%, respectively, compared with the control group. -1 was 23.28%, GGH (1) -2 was 15.84%, and GGH (1) -3 was 24.60% (FIG.

② Liver tissue  Fat accumulation change

Compared with the control group, fat mass was significantly decreased in GGH (1) -1 and GGH (1) -3, which showed the greatest decrease in body weight and fat weight (FIG. 16).

Claims (6)

A pharmaceutical composition for the prevention and treatment of obesity, comprising an extract of a mixture of ganoderma, a packing and a mixture of ganoderma, 50 to 70 parts by weight of ganoderma, 10 to 30 parts by weight of packing, 10 to 30 parts by weight of ganoderma.
The method of claim 1, wherein the extract is water, C ₁ To C ₄ A lower alcohol or a mixture thereof is used as a solvent.
The pharmaceutical composition according to claim 2, wherein the lower alcohol is ethanol.
delete The pharmaceutical composition for preventing and treating obesity according to claim 1, wherein the dose of the composition is 0.01 to 1000 mg / kg body weight.
A health functional food for prevention and improvement of obesity comprising an extract of a mixture of ganoderma, a packing and a mixture of ganoderma, 50 to 70 parts by weight of ganoderma, 10 to 30 parts by weight of packing, 10 to 30 parts by weight of ganoderma.

Images